ArticleThe American journal of gastroenterology2012
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).
Article in The American journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis.Rheumatology international · 2018Pooled it
- Guideline
- The First 24 Hours of Hospital Admission: Early Opportunity for Pharmacotherapy Optimization in Elderly Patients with Chronic Kidney Disease.Pharmacy (Basel, Switzerland) · 2026Article
- Article
- Impact of Proton Pump Inhibitor Therapy on Bone Mineral Density: An Updated Systematic Review.Cureus · 2026Review
- Regular Proton-Pump Inhibitor Intake is Associated with Deterioration of Peripheral Bone Mineral Density, Microarchitecture, and Strength in Older Patients as Assessed by High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT).Calcified tissue international · 2025Article
- Proton Pump Inhibitors (PPIs)-An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing.Medicina (Kaunas, Lithuania) · 2025Review
- Proton pump inhibitor exposure, trabecular bone score, and BMD: a registry-based cohort study.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Article
- Sex-specific Association of Chronic Proton Pump Inhibitor Use With Reduced Bone Density and Quality.The Journal of clinical endocrinology and metabolism · 2025Article
- Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density.Future science OA · 2024Article
- The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture-results of a large observational cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023Observational
- PPI-Induced Changes in Plasma Metabolite Levels Influence Total Hip Bone Mineral Density in a UK Cohort.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2023Article
- Proton Pump Inhibitors in Allergy: Benefits and Risks.The journal of allergy and clinical immunology. In practice · 2022Review
- Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?Bone reports · 2021Article
- Acid-Suppressive Drugs and Risk of Fracture in Children and Young Adults: A Meta-Analysis of Observational Studies.Frontiers in pharmacology · 2021Review
- Effect of proton pump inhibitors on bone mineral density: A systematic review and meta-analysis of observational studies.Bone reports · 2020Review
- Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review).Journal of clinical medicine · 2020Review
- Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study.The Korean journal of internal medicine · 2020Article
- Older Patient and Caregiver Perspectives on Medication Value and Deprescribing: A Qualitative Study.Journal of the American Geriatrics Society · 2020Article
- Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship.The Permanente journal · 2020Article
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
12 authors.
Funding
Abstract
objectivesProton pump inhibitor (PPI) use has been identified as a risk factor for hip and vertebral fractures. Evidence supporting a relationship between PPI use and osteoporosis remains scant. Demonstrating that PPIs are associated with accelerated bone mineral density (BMD) loss would provide supportive evidence for a mechanism through which PPIs could increase fracture risk.
methodsWe used the Canadian Multicentre Osteoporosis Study data set, which enrolled a population-based sample of Canadians who underwent BMD testing of the femoral neck, total hip, and lumbar spine (L1-L4) at baseline, and then again at 5 and 10 years. Participants also reported drug use and exposure to risk factors for osteoporosis and fracture. Multivariate linear regression was used to determine the independent association of PPI exposure and baseline BMD, and on change in BMD at 5 and 10 years.
resultsIn all, 8,340 subjects were included in the baseline analysis, with 4,512 (55%) undergoing year 10 BMD testing. After adjusting for potential confounders, PPI use was associated with significantly lower baseline BMD at the femoral neck and total hip. PPI use was not associated with a significant acceleration in covariate-adjusted BMD loss at any measurement site after 5 and 10 years of follow-up.
conclusionsPPI users had lower BMD at baseline than PPI non-users, but PPI use over 10 years did not appear to be associated with accelerated BMD loss. The reasons for discordant findings between PPI use at baseline and during follow-up require further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.